Tetra Bio-Pharma, Alternavida Join Forces to Develop Cannabinol Product Caumz for Chronic Pain

Tetra Bio-Pharma, Alternavida Join Forces to Develop Cannabinol Product Caumz for Chronic Pain
Tetra Bio-Pharma and Alternavida have established a collaboration agreement to allow the clinical development, marketing, and distribution of the cannabis-derived medicine Caumz (PPP011) in Mexico. This agreement will potentially accelerate the progression of two ongoing clinical trials testing Caumz while the company pursues approval in the U.S. and Canada. The Serenity Phase 3 trial is testing Caumz as a treatment for advanced cancer-associated pain, while another Phase 2 trial evaluates the medication's safety and efficacy for fibromyalgia. “We are thrilled to have signed this clinical development and commercialization agreement with Alternavida, as it provides non-dilutive funding for two clinical sites as well as a solid commercial footprint in Mexico, with the potential to expand to eight additional territories in Latin America,” Guy Chamberland, CEO and chief regulatory officer of Tetra, said in a press release. “Tetra will now be operating clinical sites in three countries: Mexico, Canada, and the U.S., boosting our enrollment potential." Caumz is an investigational non-opioid alternative to treat pain. It is an inhaled medical cannabis product, composed of pure synthe
Subscribe or to access all post and page content.